Live Biotherapeutic Products – a new regulatory approach for the safety assessment of a specific category of biological medicinal products NARBONNE, France – An article has been published in Frontiers in Medicine: Regulatory Science section, which proposes a new set of recommendations for addressing the various regulatory and technical challenges when assessing the safety of […]
The following is an open letter to the Members of the Pharmabiotic Research Institute (PRI). Dear Members, partners and friends of the Pharmabiotic Research Institute (PRI), As the year 2019 ends, we find ourselves reflecting on the last 12 months and what has been learned, discussed, accomplished, and what work still lies ahead… In 2020 […]
Written by Kristina Campbell – This article originally appeared in the online publication The Microbiome Times Many individuals living with chronic disease—whether it’s asthma, allergies, atopic dermatitis, type 2 diabetes, or another condition—readily confirm their therapeutic options leave a lot to be desired. Even if an existing drug product deals adequately with their symptoms, it often […]
“Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma, in coordination with the Pharmabiotic Research Institute (PRI), are working in collaboration within the ‘Intestinal Microbiome-based Medicines European Task Group (IMM-ETG)’ to propose a harmonised, pan-European, regulatory approach to intestinal microbiome whole ecosystem[1]-based therapeutics” Monday, 20 May 2019 – Caelus Health, EnteroBiotix, Ferring Pharmaceuticals, and MaaT Pharma […]
The following web article is an update on the status of the PRI’s operations and initiatives for the current fiscal year (October 2018 – September 2019). This information was previously communicated to the PRI Members in a dedicated e-mail. Dear members, partners and friends of the Pharmabiotic Research Institute (PRI), 2019 has already been […]
